Invasive fungal infections (IFI) are the leading cause of infectious mortality in adult patients undergoing hematopoietic cell transplantation (HCT) after myeloablative conditioning, but the extent of this problem in the pediatric population is unclear. We retrospectively examined risk factors for IFI among 120 consecutive pediatric patients undergoing allogeneic HCT at a single center. The incidence of proven or probable IFI in pediatric patients during the first year after allogeneic HCT was 13%, comparable to the rate reported in adult patients; however, unlike IFI in adult patients, the majority of IFI in children occurred within the first month after transplantation. The primary risk factors for IFI were duration of neutropenia, age greater than 10 years, transplant for severe aplastic anemia or Fanconi anemia, and high-dose corticosteroid administration for 10 days or longer. IFI were more likely to be successfully treated (42%, 5/12 patients) in pediatric HCT recipients when compared to previous reports of adult recipients. Nonrelapse mortality was estimated at 17% (20/120 patients) after allogeneic HCT, of which 35% (seven patients) were directly attributed to IFI. Thus, IFI is a significant cause of nonrelapse mortality in children undergoing allogeneic HCT and more effective strategies are needed to prevent and treat IFI. Bone Marrow Transplantation (2005) 36, 621-629.
transplantation; children Hematopoietic cell transplantation (HCT) has greatly expanded effective treatment options and improved the survival of children with high-risk malignant disorders and bone marrow (BM) failure syndromes. 1 Invasive fungal infections (IFI) are currently the leading cause of infectious mortality in adult patients undergoing allogeneic HCT. Although prophylaxis with fluconazole has successfully decreased the incidence of infections caused by susceptible Candida spp, infections caused by resistant Candida spp and moulds, such as Aspergillus, Fusarium, and Scedosporium, have subsequently increased.
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The incidence of IFI among pediatric patients undergoing allogeneic HCT has been less well described. Several retrospective pediatric reviews have reported incidence rates of documented IFI ranging from 6 to 12%, with overall mortality rates of 4-14%. [7] [8] [9] Many patients in need of allogeneic HCT have undergone intensive pre-transplant chemotherapy regimens and have experienced a prior IFI. Although several case series describe the outcome of adults with prior IFI who undergo HCT, [10] [11] [12] [13] there are only sporadic case reports in the pediatric population.
14, 15 Here, we report the incidence, risk factors, and outcomes of IFI in 126 consecutive pediatric patients who underwent allogeneic HCT following a myeloablative preparative regimen at Lucile Packard Children's Hospital (LPCH) at Stanford University Medical Center during a 6-year period (1998) (1999) (2000) (2001) (2002) (2003) (2004) ).
Patients and methods

Study patients
This retrospective analysis was approved by the Stanford University School of Medicine Institutional Review Board. Medical records of 126 consecutive pediatric patients who underwent myeloablative allogeneic HCT at LPCH between September 1998 and September 2004 were reviewed. Six patients who had a known history of IFI (Aspergillus spp, n ¼ 5; Mucor spp, n ¼ 1) prior to HCT were analyzed separately. Five patients were determined to have possible IFI and were excluded from the analysis.
Between October 4, 2001 and February 16, 2004 , demolition of an old building and construction of a new facility took place immediately adjacent to LPCH. Patients were determined to have had their transplant during construction if their date of transplant fell between 1 month prior to the start of construction until the end of construction. Season of transplantation was defined by the date of transplantation (D þ 0) occurring from December to February (winter), March-May (spring), June-August (summer), or September-November (fall).
Graft-versus-host disease (GVHD) prophylaxis and treatment
GVHD prophylaxis remained constant throughout the study period and consisted of intravenous (i.v.) methotrexate 15 mg/m 2 on D þ 1, then 10 mg/m 2 on D þ 3, D þ 6, and D þ 11, and cyclosporin A (CSA) at a dose of 5 mg/kg/day i.v. daily from DÀ2 to D þ 3, followed by 3 mg/kg/day i.v. daily from D þ 4 to Dþ 14, then 3.75 mg/kg/day i.v. divided twice daily until the patient is able to take oral medications. At that point, the current i.v. dose is tripled and the oral dose adjusted for a level of 200-300 ng/ml. In the absence of GVHD, the dose of CSA was tapered beginning at D þ 120 with the last dose scheduled to be given on D þ 180 in children under 11 years of age or D þ 270 in children 11 years of age and older. Tapering schedules were modified at the discretion of the attending physicians by disease status and activity of GVHD. Diagnosis and clinical grading of acute and chronic GVHD were performed according to established criteria. 16, 17 Acute and chronic GVHD were treated at the discretion of the attending physicians with 0.5-2 mg/kg/day of prednisolone equivalents, resumption of CSA administration if the dose had been tapered, or both. A small number of patients (n ¼ 8) were unable to tolerate CSA and required treatment with tacrolimus (0.2-0.3 mg/kg/day; n ¼ 4) or mycophenolate mofetil (600 mg/m 2 /dose twice daily; n ¼ 6) or both. No patients were treated with monoclonal antibodies for acute or chronic GVHD.
Infection prophylaxis and monitoring
Until neutrophil engraftment, defined as an absolute neutrophil count greater than 500 cells/ml for 2 consecutive days, patients were housed in double-door high-efficiency particulate air (HEPA)-filtered isolation rooms and provided low microbial diets. Patients who had a positive pretransplant serology for herpes simplex virus received acyclovir (250 mg/m 2 i.v. three times daily) from day of admission until D þ 30 or discharge. Human granulocytecolony stimulating factor was not routinely administered after transplantation. Post-engraftment care included the following: (1) patients were instructed to wear HEPAfiltered masks while outside of their room; (2) cotrimoxazole or pentamidine was administered as prophylaxis against Pneumocystis carinii pneumonia (PCP); and (3) i.v. immunoglobulins (IVIG) were infused monthly (DÀ8 through D þ 180). Patients who had a positive pretransplant serology for cytomegalovirus (CMV) or who received grafts from CMV-positive donors received ganciclovir (5 mg/kg i.v. twice daily) starting from the date of neutrophil engraftment until D þ 100. The COBAS AMPLICOR system (Roche, Basel, Switzerland) to detect CMV using polymerase chain reaction (PCR) was used as weekly screening of patients at risk for CMV disease through D þ 180.
From September 1998 to August 2002, low-dose i.v. amphotericin B deoxycholate (Fungizonet, 0.15 mg/kg/ day) was used beginning on D þ 0 through date of discharge. 18 Upon discharge, fluconazole (Diflucant, 5 mg/kg/day p.o.) was given to all patients until D þ 100, or longer for those patients who remained on corticosteroids for the treatment of GVHD. After August 2002, fluconazole (5 mg/kg/day p.o. or i.v.) beginning on the day of admission was used for prophylaxis.
Patients with fever X38.01C received empiric antibacterial therapy with vancomycin and an anti-pseudomonal agent. If the fever persisted for 5-7 days after modification of anti-bacterial therapy, an amphotericin B formulation was added. Initial dosage of amphotericin B deoxycholate was 1 mg/kg/dose i.v. daily, liposomal amphotericin B (Ambisomet) was 5 mg/kg/dose i.v. daily, and amphotericin B lipid complex (Abelcett) was 5 mg/kg/dose i.v. daily. Patients treated with a formulation of amphotericin B for prolonged fever without source had negative computerized tomography (CT) scans of their sinuses, chest, abdomen, and pelvis prior to discontinuation of their anti-fungal agent. Duration of treatment for patients with IFI was left to the discretion of the attending physician, but at a minimum lasted until resolution of fever and either negative blood cultures or any measurable disease by high-resolution CT scan. Patients receiving treatment for chronic GVHD were maintained on prophylaxis for PCP and started on penicillin for prophylaxis of encapsulated bacterial organisms.
Definitions and statistical analyses
In this study, we identified patients who developed proven, probable, or possible IFI at any point after their HCT using standardized definitions set forth by the European Organization for Research and Treatment of Cancer and the National Institute of Allergy and Infectious Diseases Mycoses Study Group. 19 CMV reactivation was defined as the presence of a positive blood PCR in the absence of clinical disease. Categorical values were compared using w 2 and Fisher's exact tests. Continuous variables were compared using unpaired two-tailed t-test. A P-value of o0.05 was considered statistically significant.
Results
Study patients and clinical outcomes after allogeneic HCT
After exclusion of the six patients with prior IFI and the five patients with possible IFI, characteristics of the remaining 115 patients are summarized in Table 1 . Median age was 8.7 years (range: 0-20 years). Most (87%) had hematologic malignancies as their underlying condition for transplantation. Four patients (3%) had received previous autologous or allogeneic stem cell transplants with myeloablative conditioning. The overall mortality of the patients in this study was 37% (43/115). The nonrelapse mortality was 17% (20/115). In the 15 patients with proven/probable IFI, four patients are alive, seven patients were determined to have died from fungal disease, two patients were determined to have died of non-fungal causes (Enterobacter cloacae sepsis ¼ 1; hypoxic ischemic encephalopathy ¼ 1), and two patients were determined to have expired from relapse. Thus, the overall mortality in the group with IFI was 73% (11/15), with a nonrelapse mortality of 69% (9/13).
In contrast, in the group of 100 patients with no evidence of IFI, 68 patients are alive, 11 patients were determined to have expired from toxicity attributable to HCT (multisystem organ failure ¼ 5; acute respiratory distress syndrome ¼ 2; bacterial sepsis ¼ 1; human herpesvirus-6 ¼ 1; veno-occlusive disease of the liver ¼ 1; pulmonary hemorrhage ¼ 1), and 21 patients were determined to have expired from relapse. Thus, the overall mortality in the group without IFI was 32% (32/100), with a nonrelapse mortality of 14% (11/79). Therefore, in the entire population of 115 patients, the overall mortality attributed to IFI was 6% (7/115), which accounted for 35% (7/20) of the nonrelapse deaths in this study.
Incidence and timing of IFIs
The cumulative incidence of proven (9.2%; 11/120), probable (3.3%; 4/120), or possible (4.2%; 5/120) IFI during the first year after allogeneic HCT was 16.7% (20/ 120). Five patients were determined to have possible IFI on the basis of prolonged fever without source, characteristic findings on pulmonary CT scan, and rapid resolution of fever after initiation of anti-fungal therapy. However, since diagnostic bronchoscopic examinations were not performed on these patients, and thus, no organisms were isolated, these patients were excluded from further analysis. In patients with proven/probable IFI, the median time from the date of transplant to the onset of infection was 25 days (range, 7-215 days). Infections with Candida spp occurred at a median of 20 days (range, 7-27 days), while infections with Aspergillus spp occurred at a median of 26 days (range, 13-107 days). Three patients with IFI were determined to have graft failure, as evidenced by no signs of neutrophil recovery by D þ 60 and a severely hypocellular BM, a known risk factor for late-onset fungal disease. 20 In the 12 patients without graft failure, five cases of IFI (42%) were diagnosed very early (o14 days) after HCT, five cases (42%) were diagnosed between 14 and 28 days after HCT, and only two cases (16%) were diagnosed later than a month following HCT.
Aspergillus spp (n ¼ 8) were the most frequently identified (53%) organisms (Figure 1 ). Candida albicans (n ¼ 2) and non-C. albicans spp (n ¼ 3) accounted for 33% of identified IFI. All three non-C. albicans spp had high minimal inhibitory concentrations to fluconazole (8-16 mg/ml), suggesting in vitro anti-fungal resistance.
Risk factors for IFIs
Univariate analysis revealed several possible risk factors for IFI (Tables 1 and 2 ). Increased risk of developing IFI was associated with: (1) patients who received 2 mg/kg/day or greater of corticosteroids for 10 days or longer (RR ¼ 13.3; 95% CI 1.8-99.8); (2) duration of neutropenia greater than 28 days (RR ¼ 3.9; 95% CI 1.6-9.7); (3) patients older than 10 years of age (RR ¼ 3.1; 95% CI 1.5-9.2); and (4) patients with severe aplastic anemia (SAA) or Fanconi anemia (FA) (RR ¼ 2.9; 95% CI 1.1-7.7).
Trends towards an increased risk of developing IFI were associated with the following: (1) CMV disease (RR 3.8; 95% CI 1.3-11.4); (2) acute GVHD grades III-IV (RR 3.4; 95% CI 1.8-9.6); and (3) acute GVHD grades II-IV (RR 2.8; 95% CI 0.98-8.0). However, the following variables were not significant according to univariate analysis: patient sex, transplant number, donor, stem cell source, conditioning regimen, season of transplantation, presence of nearby construction, type of fungal prophylaxis, chronic extensive GVHD, corticosteroid peak dose, or CMV reactivation.
Outcomes after IFIs
Patients with proven/probable IFI had significantly higher mortality from all causes (73% mortality) than those 1 Fusarium (blood) Figure 1 Organisms and sites of IFI in pediatric allogeneic HCT patients.
Fungal infections in pediatric transplantation CC Dvorak et al without IFI (32% mortality, P ¼ 0.003). When patients with relapsed disease are excluded from the analysis, the association of IFI with death is even stronger (69 vs 14% mortality, P ¼ 0.0001). The relative risk of dying from a nonrelapse-related cause was significantly greater in the IFI group compared to the group without IFI (RR ¼ 5.0; 95% CI 2.6-9.6).
In the 15 patients with proven/probable IFI, three patients died of alternate causes before resolution of their fungal disease. In the remaining 12 patients, five patients (42%) resolved and seven patients (58%) died of their disease. Although invasive aspergillosis appears to be more difficult to resolve (33%, 2/6 patients) than invasive infections with Candida spp (75%, 3/4 patients), the power is lacking for statistical significance.
All patients with IFI were treated with amphotericin B (1 mg/kg/dose i.v. daily; n ¼ 5), liposomal amphotericin B (5 mg/kg/dose i.v. daily; n ¼ 10), or amphotericin B lipid complex (5 mg/kg/dose i.v. daily; n ¼ 2). For those patients with evidence of resolving disease, administration was decreased to [5] [6] 
Safety of allogeneic HCT in patients with prior history of IFIs
Six patients were known to have proven IFI prior to HCT (Table 3 ). All had refractory disease with HCT representing their only chance for curative therapy. Five had a history of invasive pulmonary aspergillosis (one patient had both pulmonary and cutaneous disease), and one had a history of maxillary zygomycosis. All six patients had undergone surgical debridement and received perioperative anti-fungal therapy for the entire interval prior to transplantation. All patients received secondary fungal prophylaxis until engraftment with either a formulation of amphotericin B (n ¼ 5) at treatment doses or voriconazole (4 mg/kg/dose i.v. twice daily, n ¼ 1).
Of the three patients who survived greater than 60 days, only one (patient #4) developed a recurrence of their invasive aspergillosis on D þ 133, who was successfully treated. None of the patients who died prior to D þ 60 had evidence of fungal recurrence at the time of death.
Incidence and duration of empiric anti-fungal therapy in patients without IFIs
Excluding patients with a prior history of IFI, 100 patients (83%) were found to have no evidence of invasive fungal disease. Of these, 66% (66/100 patients) were treated empirically for prolonged fever without identified source with anti-fungal agents. In all, 18 patients received amphotericin B; 36 patients received amphotericin B liposomal complex; 10 patients received amphotericin lipid complex; one patient received caspofungin; and one patient received simultaneous caspofungin and voriconazole.
The patients who received prophylaxis with fluconazole alone (36/100) were equally likely to be treated empirically with anti-fungals (61%) than those receiving prophylaxis with low-dose amphotericin B plus fluconazole (64/100 patients; 70%; P ¼ 0.38). In those patients who received empiric therapy with one of the formulations of ampho- tericin B, the median duration of therapy was 14.1710.3 days (range, 2-57 days). In the patients with no evidence of IFI, there was no difference in nonrelapse mortality between the group that received empiric anti-fungal therapy (12%) and the group that did not (9%, P ¼ 0.75).
Discussion
Incidence and risk factors
This study demonstrates that the cumulative incidence of proven or probable IFI after allogeneic HCT in pediatric patients was 13% in the cohort studied. Recent reports have indicated that the incidence rates of IFI in adult patients undergoing allogeneic HCT range from 6 to 19%. [21] [22] [23] Invasive aspergillosis alone has an incidence rate of 4-15%. 2, 21, 24 Studies of pediatric populations undergoing HCT show an incidence rate of IFI ranging from 3-21%. [7] [8] [9] [25] [26] [27] However, many of these studies included autologous HCT patients in the analysis (a group known to have decreased risk of IFI 28 ), suggesting that their incidence of IFI may be underestimated. As we used a conservative definition of IFI (possible cases were excluded from the analysis), we may have underestimated the true infection rate in our allogeneic HCT population.
The median time from the date of transplant to the onset of proven/probable IFI with Candida spp in our cohort was 20 days, similar to results in adults, which show that the peak onset of IFI with Candida spp is at 2 weeks after HCT. 27 In adults, IFI with Aspergillus spp have a bimodal distribution, with a first peak at a median of 16 days and the second at a median of 96 days after HCT. 29 The median time to onset of proven/probable IFI with Aspergillus spp in our cohort was 26 days. However, our cohort also showed a bimodal distribution, with the two patients with graft failure developing IFI at D þ 101 and D þ 107, and the remaining six patients developing IFI at a median of 22 days from the date of transplant. These data show the majority of IFI being diagnosed within the first month following transplant, in contrast to a prior single-center report in children showing only 25% of IFI being diagnosed within the first 30 days, 7 suggesting the need for confirmation at other institutions. Nevertheless, this information may be useful in determining the duration of anti-fungal prophylaxis needed for the pediatric patient population without risk factors for late-onset IFI.
This study shows significantly fewer IFI in patients under 10 years of age (7%) than in patients 10 years of age and older (20%). To our knowledge, this has not been previously reported. This may reflect the importance of host colonization by environmental fungus as an important step in the development of invasive disease, with younger patients having had less exposure time to fungal spores in the environment. 20 This study shows significantly more invasive fungal disease in patients with SAA or FA (46%) than compared to other diagnoses (14%). This finding may also reflect the importance of host colonization, with those patients with prolonged defects in all components of their immune system (as seen in patients with SAA) at higher risk for pre-HCT colonization. One study has shown a high incidence of IFI (26%) in patients with FA, but this group was not compared to HCT patients without FA. 30 Another group reported an incidence of only 8% (1/12) in FA patients without leukemic transformation, but a surprisingly high incidence of 60% (3/5) in FA patients with leukemic transformation. 31 Interestingly, both of our FA patients who had undergone leukemic transformation had IFI. The intrinsic DNA repair defect in patients with FA increases their sensitivity to radiation and chemotherapeutic agents; therefore, the finding of IFI may reflect an increased sensitivity of the immune system in FA patients to the conditioning agents used for the HCT. Those FA patients who also need induction chemotherapy prior to HCT in order to bring their leukemia into remission may be at even higher risk.
This study shows significantly more IFI in patients with delayed neutrophil recovery over 28 days, a result that corroborates those of other studies reporting the association of IFI with prolonged neutropenia. [5] [6] [7] This finding has significant implications when performing HCT from donor sources in which delayed engraftment might be expected, although we did not see a significant difference in incidence of IFI between peripheral blood stem cells (PBSC) (20%) vs BM (12%), despite the fact that the median time to engraftment was shorter in the PBSC group compared with the BM group (1677.5 vs 21.774.9 days, respectively).
Several studies have reported that acute GVHD and its treatment with corticosteroids are an important risk factors for the development of IFI after allogeneic HSCT. 6, 7, 9, 21, 32 Our study did show trends towards a statistical significant association of IFI with either acute GVHD grades II-IV or grades III-IV, and it is possible that with an increased sample size, an association would have been found. It is unclear whether the pathophysiology of GVHD per se increases the risk of IFI, or if GVHD is simply an indicator of which patients receive corticosteroids. Although we did not see an association with peak corticosteroid dose and development of IFI, we did find that those patients who received high-dose corticosteroids (2 mg/kg/day or more prednisolone equivalents) for 10 days or longer had an increased risk of developing IFI. Chronic extensive GVHD has also been reported to be a risk factor for IFI; 6, 7, 32 however, in our cohort, there was no trend towards increased IFI in patients with chronic extensive GVHD, likely because of the very small number of late-onset fungal infections in our patients (three cases after D þ 100). Since the pathophysiology of chronic GVHD in our patient cohort is presumably similar to that seen in other studies, it is possible that the lack of association of chronic extensive GVHD with IFI in our cohort reflects variances in the treatment of chronic extensive GVHD amongst different centers.
An association between CMV disease and IFI has been demonstrated by studies in adults, although the mechanism remains unclear. 21, 32 Our study demonstrates that the detection of CMV reactivation by PCR analysis is not a risk factor for IFI in this pediatric cohort; however, there was a trend towards increased risk of IFI in patients with CMV disease. The incidence of post transplant CMV disease in our cohort (3%) was very low, possibly due to our use of prophylactic ganciclovir in high-risk patients, which may have partially abrogated this risk factor or skewed statistical analysis.
Our study confirmed the finding of other groups that low-dose amphotericin B followed by fluconazole is no more effective than fluconazole alone in preventing IFI. 23, 33 Given the extra toxicity that any amphotericin B-containing regimen contains, and the fact that amphotericin B is a concentration-dependent killing anti-fungal that is best employed at therapeutic doses for maximal effectiveness, it seems possible that low-dose amphotericin B is a poor choice for anti-fungal prophylaxis in pediatric allogeneic HCT patients.
Treatment and outcomes
Since the introduction of prophylaxis with either low-dose amphotericin B plus fluconazole or fluconazole alone, the risks of invasive candidiasis and Candida-related mortality have decreased after allogeneic HCT. 3, 4, 32 In our cohort of patients, all of whom received some form of anti-fungal prophylaxis, only two proven or probable infections (1.6% overall incidence rate) with C. albicans occurred. However, since fluconazole has no anti-Aspergillus activity, we did see an 11% incidence (13/115 patients) of Aspergillus spp, Fusarium moniliforme, Trichosporon inkin, and moderately fluconazole-resistant Candida spp, seven of which were fatal.
This study demonstrates that IFI continue to account for a significant portion of overall mortality (6%, 7/115) and nonrelapse mortality (35%, 7/20) among patients undergoing allogeneic HCT. In adult patients with IFI following allogeneic HCT, outcomes are extremely poor, with a 1-year mortality rate of 68-90%. 3, 5, 21 In pediatric patients, the data are conflicting. An Italian group reported a 4% overall fungal-related mortality and a 71% resolution rate in patients with IFI, but this study cohort was comprised of greater than 50% autologous HCT patients. 8 Conversely, a Finnish group reported an 8% overall fungal-related mortality and 33% resolution rate in patients with IFI, also with a study cohort of greater than 50% autologous HCT patients. 7 The resolution rate of 42% in this cohort of strictly allogeneic HCT patients represents a large pediatric study population, suggesting that while this is a slightly less significant problem in the pediatric setting as compared to the adult setting, a significant percentage of children continue to die from IFI after HCT. The median treatment time of 42 days in patients with successful disease resolution confirms standard treatment recommendations of 6 weeks or longer, although ultimately treatment should be individualized and continued until all signs of infection have resolved. 34 Six patients known to have IFI were analyzed separately in this study. All six patients underwent initial anti-fungal therapy with a formulation of amphotericin B, surgical debridement, and then followed by post-operative antifungal therapy prior to their HCT. Most received antifungal prophylaxis with treatment doses of a formulation of amphotericin B. Only one patient (17%) developed a recurrence of their invasive aspergillosis, an incidence rate not significantly greater than that of the patients without a history of IFI (13%). In the three long-term surviving patients, surgical resection took place greater than 3 months before HCT in those that did not recur, but only 2 months before HCT in the one patient that did recur. This suggests that longer periods of time (43 months) between resolution of prior IFI and HCT, and aggressive use of treatment-dose amphotericin B formulations during transplant may allow HCT to be carried out safely on pediatric patients with a history of IFI. Several studies in adults have shown similar rates of recurrent invasive fungal disease (14-29%). 12, 13, 35 Finally, this study demonstrates a high frequency (66%) of empiric anti-fungal therapy use in patients later determined to have no evidence of IFI. The mean duration of empiric therapy with an amphotericin B formulation was 13710 days. Other groups have reported a 37-75% frequency of empiric amphotericin B usage in children undergoing HCT for median durations of 12-28 days. 7, 25 This finding reflects awareness of risk of IFI following HCT, which has been translated into guidelines for the use of empiric anti-fungal therapy after prolonged fever without source. These findings underscore the importance of developing more effective antifungal prophylaxis strategies to decrease rates of proven and probable disease, and for new tests that may serve as the foundation for pre-emptive therapy of IFI, such as PCR or the galactomannan assay. 4, 20, 32 
Conclusion
This study was a retrospective, descriptive analysis of IFI at a single institution over a time period where the supportive care and treatment protocols were relatively consistent. Therefore, it provides some insight into IFI in the pediatric HCT population that may be useful in the design of future clinical trials. This limitations of this study include: (1) a small number of proven/probable IFI, making multivariate analysis of risk factors difficult; (2) since environmental exposure seems to play a role in the development of IFI and the study was conducted at a single institution, the incidence of IFI in these patients may reflect a regional bias that is not generalizable to other centers; and (3) the therapy of proven/probable infections was not standardized, making it difficult to draw definitive conclusions regarding efficacy of particular anti-fungal agents.
However, this study is useful in that it identifies several groups with increased rates of IFI: (1) children 10 years of age or older (20%); (2) children with the diagnosis of SAA or FA (36%); (3) children with prolonged neutropenia of greater than 4 weeks duration (38%); and (4) children receiving high-dose (2 mg/kg/day or more of prednisone equivalents) corticosteroids for 10 days or longer (55%). Likewise, trends towards an increased rate of IFI were noted in: (1) children with acute GVHD grades II-IV (20%); (2) children with acute GVHD grades III-IV (29%); and (3) children with CMV disease (50%). Given the high rates of IFI in these groups, it is likely that these patients would likely show the most benefit from participating in randomized trials comparing one standard practice of using fluconazole as primary anti-fungal prophylaxis vs newer agents with activity against moulds. Similarly, given the high rate of IFI-related mortality after allogeneic HCT (6%), more effective therapeutic strategies are urgently needed.
